1. Enzymatic activation of a doxorubicinpeptide prodrug by phosphate-specific antigen;Denmeade;Cancer Res.,1998
2. Elucidation of the mechanism enabling tumor selective prodrug monotherapy;Bosslet;Cancer Res.,1998
3. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo;Brain;Br. J. Cancer,1998
4. Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine-mediated radiosensitization in mouse and human tissues;Kinsella;Clin. Cancer Res.,1998
5. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine;Lawrence;Cancer Res.,1998